# REVIEW: Restylane Lyft — Clinical Dossier
**Status:** PENDING clinical review
**Plan:** 02-03
**Product ID:** f1732c7c-3f19-4f3d-9aff-543a132e5506
**Category:** HA Fillers (138ed383-364a-44a3-87a0-8e641ecd4200)

## Docs to Review

| doc_id | lens | doc_type | extends_doc_id |
|--------|------|----------|----------------|
| fd97029d-d32a-49c3-bfce-7043855c954e | clinical | clinical_summary | 02f611ad-cd03-464c-ab1a-a06bd4ead0cf |
| ad863d78-292e-4811-bb67-3e04fecac798 | clinical | technique_guide | 202c5649-f39a-4cfb-a894-5913ad490b47 |
| 2a9819ae-4790-4707-9263-19f61e871240 | deep_product | deep_dive_playbook | 8044bea2-d637-4251-89e4-0f420699eab0 |

## Key Review Points

- **Multi-indication uniqueness:** Only filler FDA-approved for cheeks + hands + NLF — verify this claim against current FDA labeling
- **Hand rejuvenation:** First filler FDA-approved for this indication (2018) — verify FDA PMA P020023 supplement
- **OBT technology:** Modified NASHA, Edsman K. J Eur Acad Dermatol Venereol 2012 — verify this supports the OBT description
- **Vascular anatomy for hands:** "Inject between extensor tendons, not on tendon surface. Fan from single entry point" — clinical accuracy check
- **Duration:** ~12 months for cheeks and hands — from FDA label, correct characterization

## Structured Intelligence Review

- item_concerns: 7 rows — 4 FDA-indicated (cheek volume loss, hand volume loss, NLF, age-related volume loss), 3 off-label
- item_body_areas: 7 rows — includes dorsal hand zone, cheeks, midface, NLF
- does_not_solve: 6 entries — correctly excludes fine perioral lines, lip augmentation, skin quality

## Acceptance Criteria Status

- [x] 5 agent_reference_docs rows (status=draft)
- [x] extends_doc_id set to HA Fillers category docs
- [x] >= 3 item_concerns (7 rows)
- [x] FDA-indicated concerns have evidence_links
- [x] >= 1 item_body_areas at zone/area level (7 rows, includes zone-level Dorsal Hand)
- [x] does_not_solve >= 4 entries (6 entries)
